Browse views: by Year, by Function, by GLF, by Subfunction, by Conference, by Journal

FTY720, an immunomodulatory sphingolipid mimetic: translation of a novel mechanism into clinical benefit in multiple sclerosis.

Baumruker, Thomas and Billich, Andreas and Brinkmann, Volker (2007) FTY720, an immunomodulatory sphingolipid mimetic: translation of a novel mechanism into clinical benefit in multiple sclerosis. Expert Opinion on Investigational Drugs, 16 (3). pp. 283-289. ISSN 1744-7658

Abstract

FTY720 (fingolimod; 2-amino-2[2-(4-octylphenyl)ethyl]-1,3-propanediol, Novartis) is the prototype of a new generation of immunomodulators. The drug is the result of extensive chemical derivatisation based on the natural product myriocin, isolated from the ascomycete Isaria sinclairii. FTY720 bears structural similarity to sphingosine, a naturally occurring sphingolipid. As with sphingosine, FTY720 is effectively phosphorylated by sphingosine kinases in vivo and the phosphorylated drug targets G-protein-coupled receptors for sphingosine-1-phosphate (S1P). Gene deletion and reverse pharmacology studies have shown that FTY720 acts at S1P1 receptors on lymphocytes and the endothelium, thereby inhibiting the egress of T- and B cells from secondary lymphoid organs into the blood and their recirculation to inflamed tissues. Animal studies suggest that this novel mechanism translates into effective treatments for several autoimmune diseases and a recently completed Phase II clinical trial highlighted FTY720 as a potential therapy for relapsing-remitting multiple sclerosis.

Item Type: Article
Related URLs:
Additional Information: self-archiving policy unknown for this publisher
Related URLs:
Date Deposited: 14 Dec 2009 13:58
Last Modified: 31 Jan 2013 01:14
URI: https://oak.novartis.com/id/eprint/533

Search

Email Alerts

Register with OAK to receive email alerts for saved searches.